Landmark trials established the efficacy of SGLT2 inhibitors, GLP‐1 receptor agonists and nsMRAs in treating DKD, primarily recruiting individuals with diabetes who had or were at increased risk for CVD, most of whom were treated with RAAS blockers. The gene discussed is SLC5A2; the disease is diabetic kidney disease.